Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TSBX Stock Forecast 2026-2027
$0.35
Current Price
$8.21M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to TSBX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
TSBX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+6.1%
1 Year Change
0.0%
Year-to-Date Change
-85.2%
From 52W High of $2.40
+22.4%
From 52W Low of $0.29
📊 TOP ANALYST CALLS
Did TSBX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Turnstone Biologics is one of their latest high-conviction picks.
Latest TSBX Stock Price Targets & Analyst Predictions
TSBX has shown a year-to-date change of 0.0% and a 1-year change of 6.1%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for TSBX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TSBX Analyst Ratings
0
Buy
1
Hold
0
Sell
TSBX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.35
Latest TSBX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TSBX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 14, 2024 | B of A Securities | Charlie Yang | Neutral | Downgrade | $0.50 |
| Aug 19, 2024 | B of A Securities | Geoff Meacham | Buy | Maintains | $10.00 |
| Aug 19, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $3.75 |
| Aug 15, 2023 | B of A Securities | Geoff Meacham | Buy | Initiates | $18.00 |
| Aug 15, 2023 | Piper Sandler | Joseph Catanzaro | Overweight | Initiates | $20.00 |
Turnstone Biologics Corp (TSBX) Competitors
The following stocks are similar to Turnstone Biologics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TSBX
Turnstone Biologics
mkt cap
8.21M
Turnstone Biologics Corp (TSBX) Financial Data
Turnstone Biologics Corp has a market capitalization of $8.21M with a P/E ratio of -0.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -126.7%.
Valuation Metrics
Market Cap
$8.21M
Enterprise Value
$-8,062,054
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+203.1%
Current Ratio
3.3x
Debt/Equity
2.8x
ROE
-126.7%
ROA
-57.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Turnstone Biologics Corp (TSBX) Business Model
About Turnstone Biologics Corp
What They Do
Develops novel immunotherapies for cancer treatment.
Business Model
Turnstone Biologics generates revenue through the research and development of oncolytic virus therapies, which are designed to stimulate the immune system to fight cancer. The company advances multiple clinical and preclinical programs to target various tumor types, positioning itself to potentially monetize its innovations through partnerships, licensing agreements, or by bringing new therapies to market.
Additional Information
With a strong focus on pioneering viral-based treatment strategies, Turnstone aims to contribute significantly to the oncology sector and improve patient outcomes. The company's efforts are not only crucial for advancing cancer treatment methodologies but also for influencing the broader healthcare and pharmaceutical industries.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
CEO
Dr. Sammy J. Farah M.B.A., Ph.D.
Country
United States
IPO Year
N/A
Website
turnstonebio.comTurnstone Biologics Corp (TSBX) Latest News & Analysis
Latest News
Quick Summary
Monteverde & Associates is investigating Turnstone Biologics' sale to XOMA Royalty, offering shareholders $0.34 per share plus a contingent value right.
Why It Matters
The potential investigation into Turnstone Biologics' sale raises concerns about shareholder value, which could affect stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Halper Sadeh LLC is investigating the fairness of Turnstone Biologics' sale to XOMA Royalty for $0.34 per share plus a contingent value right, urging shareholders to explore their legal options.
Why It Matters
The investigation into Turnstone Biologics' sale could indicate potential legal challenges, affecting share value and investor confidence in both companies.
Source: Business Wire
Market Sentiment:
Neutral
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
11 months ago
Quick Summary
Turnstone Biologics Corp. (Nasdaq: TSBX) reported Q1 2025 financial results and announced the discontinuation of all TIDAL-01 clinical studies as of January 2025.
Why It Matters
Turnstone's decision to halt the TIDAL-01 clinical studies raises concerns about its pipeline and future growth potential, impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Turnstone Biologics Corp. (Nasdaq: TSBX) announced its Q4 and full-year 2024 financial results and shared preclinical data on Selected TIL therapies from the November 2024 SITC Annual Meeting.
Why It Matters
Turnstone Biologics' financial results and preclinical data presentation may signal progress in its innovative cancer therapies, affecting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Turnstone Biologics Corp. (TSBX) has been upgraded to a Zacks Rank #2 (Buy), indicating improved earnings outlook and potential for stock price increase.
Why It Matters
Turnstone Biologics’ upgrade to Zacks Rank #2 signals positive earnings outlook, potentially boosting investor confidence and driving the stock price up in the near term.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Turnstone Biologics is advancing its Selected TIL technology for solid tumors, with Phase 1 trials ongoing for TIDAL-01. Preclinical data will be presented at the SITC meeting from Nov 6-10, 2024.
Why It Matters
Turnstone's advancements in tumor-reactive T cell therapy and ongoing Phase 1 trials could enhance treatment options for solid tumors, potentially increasing the company's market value and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TSBX Stock
What is Turnstone Biologics Corp's (TSBX) stock forecast for 2026?
Analyst forecasts for Turnstone Biologics Corp (TSBX) are not currently available. The stock is trading at $0.35.
Is TSBX stock a good investment in 2026?
According to current analyst ratings, TSBX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TSBX stock?
Price predictions from Wall Street analysts for TSBX are not currently available. The stock is trading at $0.35.
What is Turnstone Biologics Corp's business model?
Turnstone Biologics generates revenue through the research and development of oncolytic virus therapies, which are designed to stimulate the immune system to fight cancer. The company advances multiple clinical and preclinical programs to target various tumor types, positioning itself to potentially monetize its innovations through partnerships, licensing agreements, or by bringing new therapies to market.
What is the highest forecasted price for TSBX Turnstone Biologics Corp?
Price targets from Wall Street analysts for TSBX are not currently available. The stock is trading at $0.35.
What is the lowest forecasted price for TSBX Turnstone Biologics Corp?
Price targets from Wall Street analysts for TSBX are not currently available. The stock is trading at $0.35.
What is the overall TSBX consensus from analysts for Turnstone Biologics Corp?
The overall analyst consensus for TSBX is neutral. Out of 3 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are TSBX stock price projections?
Stock price projections, including those for Turnstone Biologics Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 9:01 PM UTC